Buy Rating on Masimo: Strategic Options and Consumer Division Value Creation Set to Boost Shareholder Returns
Buy Rating for Masimo: A Future of Strong Revenue Growth and Profitability
Masimo Analyst Ratings
Needham Keeps Their Hold Rating on Masimo (MASI)
Masimo Increasing FY24 Guidance for Healthcare Rev, Consolidated Operating Income and Consolidated EPS >MASI
Wells Fargo Maintains Masimo(MASI.US) With Buy Rating, Maintains Target Price $160
Buy Rating Affirmed: Masimo's Legal Stability and Growth Prospects Fuel Optimism
Masimo Analyst Ratings
Masimo (MASI) Receives a Hold From Needham
Masimo's Strategic Divestiture and Joint Venture Prospects Bolster Buy Rating
Masimo Analyst Ratings
Piper Sandler Upgrades Masimo to Overweight, Price Target at $160
Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $126
Piper Sandler Keeps Their Hold Rating on Masimo (MASI)
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)
Masimo Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Masimo (MASI), Halozyme (HALO) and McKesson (MCK)
Buy Rating Affirmed for Masimo Amidst Stable Financials and Strategic Business Optimism
Stifel Upgrades Masimo to Buy, Sees Room for Share Price Appreciation
Masimo Analyst Ratings